{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:51Z","timestamp":1794047451783,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of mature T-cell neoplasms with an unfavorable prognosis; presentation with stage I(E) disease is uncommon. In clinical practice, an abbreviated chemotherapy treatment regimen combined with radiotherapy (combined modality treatment [CMT]) is commonly used, although evidence from clinical trials is lacking. The aim of this nationwide population-based cohort study is to describe first-line treatment and outcome of patients with stage I(E) PTCL. All newly diagnosed patients \u226518 years with stage I(E) anaplastic large cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma NOS (PTCL not otherise specified [NOS]) in 1989-2020 were identified in the Netherlands Cancer Registry. Patients were categorized according to treatment regimen, i.e., chemotherapy (CT), radiotherapy (RT), CMT, other therapy and no treatment. The primary endpoint was overall survival (OS). Patients with stage I(E) ALCL, AITL and PTCL NOS (n=576) were most commonly treated with CMT (28%) or CT (29%), 2% underwent SCT. RT only was given in 18%, and 8% received other therapy and 16% no treatment. Overall, the 5-year OS was 59%. According to subtype, 5-year OS was superior for ALCL as compared to PTCL NOS and AITL (68% vs. 55% and 52%, respectively; P=0.03). For patients treated with CMT, 5-year OS was significantly higher (72%) as compared to patients treated with either CT or RT alone (55% and 55%, respectively; P&lt;0.01). In multivariable analysis, age per year increment (hazard ratio [HR] =1.06, 95% confidence interval [CI]: 1.05-1.07), male sex (HR=1.53, 95% CI: 1.23-1.90), and CT, or no treatment (HR=1.64, 95% CI: 1.21-2.21, and HR=1.55, 95% CI: 1.10-2.17, respectively) were associated with a higher risk of mortality. For stage I(E) ALCL, AITL and PTCL NOS, 5-year OS is 59%, comparing favorably to historical outcome in advanced-stage disease. Superior outcome estimates were observed in patients treated with CMT.<\/jats:p>","DOI":"10.3324\/haematol.2023.283174","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T03:05:53Z","timestamp":1696475153000},"page":"1163-1170","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands"],"prefix":"10.3324","volume":"109","author":[{"given":"Frederik O.","family":"Meeuwes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein W.M.","family":"Van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J. Sherida H.","family":"Woei-A-Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J.","family":"Neelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne P.G.","family":"Crijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurien A.","family":"Dani\u00ebls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd J.F.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost S.P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin A.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"59641","unstructured":"Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer. 2017."},{"key":"59642","doi-asserted-by":"crossref","unstructured":"Stewart BW, Wild CP. World Cancer Report 2014. 2014;482-491.","DOI":"10.12968\/nuwa.2014.10.2.1142051"},{"key":"59643","doi-asserted-by":"crossref","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014; 124(10):1570-1577.","DOI":"10.1182\/blood-2014-04-573089"},{"key":"59644","doi-asserted-by":"crossref","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"59645","doi-asserted-by":"crossref","unstructured":"Foss FM, Horwitz SM, Civallero M. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol. 2020; 95(2):151-155.","DOI":"10.1002\/ajh.25674"},{"key":"59646","doi-asserted-by":"crossref","unstructured":"Petrich AM, Helenowski IB, Bryan LJ, Rozell SA, Galamaga R, Nabhan C. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. Br J Haematol. 2014; 168(5):708.","DOI":"10.1111\/bjh.13202"},{"key":"59647","doi-asserted-by":"crossref","unstructured":"Cederleuf H, Hjort Jakobsen L, Ellin F. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. Leuk Lymphoma. 2017; 58(12):2815.","DOI":"10.1080\/10428194.2017.1300888"},{"key":"59648","doi-asserted-by":"crossref","unstructured":"Brink M, Meeuwes FO, Van der Poel MWM. Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022; 140(9):1009-1019.","DOI":"10.1182\/blood.2021015114"},{"key":"59649","doi-asserted-by":"crossref","unstructured":"Horwitz S, O\u2019Connor OA, Pro B. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised phase 3 trial. Lancet. 2019; 393(10168):229-240.","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"59650","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104(3):634-641.","DOI":"10.1182\/blood-2003-06-2095"},{"key":"59651","doi-asserted-by":"crossref","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010; 116(18):3418-3425.","DOI":"10.1182\/blood-2010-02-270785"},{"key":"59652","doi-asserted-by":"crossref","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009; 27(1):106-113.","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"59653","doi-asserted-by":"crossref","unstructured":"Park SI, Horwitz SM, Foss FM. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019; 125(9):1507-1517.","DOI":"10.1002\/cncr.31861"},{"key":"59654","doi-asserted-by":"crossref","unstructured":"Fossard G, Broussais F, Coelho I. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018; 29(3):715-723.","DOI":"10.1093\/annonc\/mdx787"},{"key":"59655","doi-asserted-by":"crossref","unstructured":"Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R. Outcome of limited-stage peripheral T-cell lymphoma after CHOP(-like) therapy: a population based study of 239 patients from the Nordic lymphoma epidemiology group. Am J Hematol. 2023; 98(3):388-397.","DOI":"10.1002\/ajh.26803"},{"key":"59656","doi-asserted-by":"crossref","unstructured":"Chen Z, Huang H, Li X. Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified. Front Oncol. 2021; 11:607145.","DOI":"10.3389\/fonc.2021.607145"},{"key":"59657","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-L\u00f3pez JL, Patel AK, Balasubramani GK, Glaser SM, Beriwal S, Vargo JA. Treatment selection and survival outcomes in early-stage peripheral T-cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy?. Leuk Lymphoma. 2021; 62(3):538-548.","DOI":"10.1080\/10428194.2020.1842398"},{"key":"59658","doi-asserted-by":"crossref","unstructured":"Miller TP, Dahlberg S, Cassady JR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998; 339(1):21-26.","DOI":"10.1056\/NEJM199807023390104"},{"key":"59659","doi-asserted-by":"crossref","unstructured":"Schouten LJ, H\u00f6ppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993; 22(3):369-376.","DOI":"10.1093\/ije\/22.3.369"},{"key":"59660","doi-asserted-by":"crossref","unstructured":"Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F. Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. Br J Haematol. 2021; 192(1):82-99.","DOI":"10.1111\/bjh.16741"},{"key":"59661","doi-asserted-by":"crossref","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; 15(10):1467-1475.","DOI":"10.1093\/annonc\/mdh392"},{"key":"59662","doi-asserted-by":"crossref","unstructured":"Carson KR, Horwitz SM, Pinter-Brown LC. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017; 123(7):1174.","DOI":"10.1002\/cncr.30416"},{"key":"59663","doi-asserted-by":"crossref","unstructured":"Kameoka Y, Takahashi N, Itou S. Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma. Int J Hematol. 2015; 101(6):536-542.","DOI":"10.1007\/s12185-015-1763-7"},{"key":"59664","doi-asserted-by":"crossref","unstructured":"De Leval L, Parrens M, Le Bras F. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015; 100(9):e361-364.","DOI":"10.3324\/haematol.2015.126300"},{"key":"59665","doi-asserted-by":"crossref","unstructured":"Wulf GG, Altmann B, Ziepert M. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial. Leukemia. 2021; 35(1):143-155.","DOI":"10.1038\/s41375-020-0838-5"},{"key":"59666","doi-asserted-by":"crossref","unstructured":"Bachy E, Camus V, Thieblemont C. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2021; 40(3):242-251.","DOI":"10.1200\/JCO.21.01815"},{"key":"59667","doi-asserted-by":"crossref","unstructured":"Ruan J, Moskowitz AJ, Metha-Shah N. High rates of remission with the initial treatment of oral azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL): clinical outcomes and biomarker analysis of a multi-center phase II study. Blood. 2021; 138:138.","DOI":"10.1182\/blood-2021-145495"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283174\/76159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283174\/76782","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11290\/76159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:01Z","timestamp":1794045901000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283174","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,5]]}}}